Neurotropism and Neuroinflammation in COVID-19 Patients With Delirium.

Summary

Emerging evidence indicates that SARS-CoV-2, the etiologic agent of COVID-19, can cause neurological, neuropsychological and psychiatric complications. Given the global dimensions of the current pandemic, there is to consider the possible large-scale neurocognitive impact of COVID-19. Therefore, there is an urgent need for longitudinal studies to determine the acute and chronic effects that COVID-19 may have on the Central Nervous System. These putative effects include the possibility that the CNS serves as a reservoir for the virus, and that COVID-19 triggers CNS deleterious inflammatory cascades and neurodegenerative process. The public implications of these effects are very important in the long term.

Conditions

• Covid19
• Delirium
• Post-traumatic Stress Disorder

Interventions

BIOLOGICAL

serology testing profiles description

SARS-CoV-2 quasispecies detection and associated serology testing profiles description (peripheral blood and cerebrospinal fluid - CSF)

BIOLOGICAL

immune response characterization

systemic and central immune response characterization , associated to the assessment of CNS damage biomarkers (peripheral blood and CSF)

OTHER

in vivo brain PET-TSPO acquisitions

in vivo brain PET-TSPO acquisitions (Positon Emission Tomography using a radioligand that targets the Translocator Protein, which is upregulated in activated microglia)

OTHER

brain MRI assessment

structural/functional brain MRI assessment (PWI/DWI mismatch imaging, quantification of gray and white matter microstructural integrity, DTI, functional connectivity)

BEHAVIORAL

neurocognitive assessment

multi-domains neurocognitive assessment

Sponsors & Collaborators

• Institut National de la Santé Et de la Recherche Médicale, France

  collaborator OTHER_GOV

• University Hospital, Toulouse

  lead OTHER

Principal Investigators

• Stein SILVA, MD, PhD · University Hospital, Toulouse

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-06-01

Primary Completion

2022-06-30

Completion

2022-06-30

Countries

• France

Study Locations